Article Versions Notes

Quagliariello V, De Laurentiis M, Cocco S, Rea G, Bonelli A, Caronna A, Lombari MC, Conforti G, Berretta M, Botti G, et al. NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences. 2020; 21(20):7802. https://doi.org/10.3390/ijms21207802

Quagliariello, Vincenzo, Michelino De Laurentiis, Stefania Cocco, Giuseppina Rea, Annamaria Bonelli, Antonietta Caronna, Maria Cristina Lombari, Gabriele Conforti, Massimiliano Berretta, Gerardo Botti, and et al. 2020. "NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells" International Journal of Molecular Sciences 21, no. 20: 7802. https://doi.org/10.3390/ijms21207802

Quagliariello, V., De Laurentiis, M., Cocco, S., Rea, G., Bonelli, A., Caronna, A., Lombari, M. C., Conforti, G., Berretta, M., Botti, G., & Maurea, N. (2020). NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences, 21(20), 7802. https://doi.org/10.3390/ijms21207802